fill
Listen On
IL-23

Data review from the Phase III Discover-2 Trials

Join Jessica Farrell, a clinical pharmacist at Albany Medical Center's Division of Rheumatology and faculty member at Albany College of Pharmacy and Health Sciences, as she reviews data from the Phase III DISCOVER-2 trials. These trials evaluate the long-term efficacy and safety of guselkumab in biologic-naive patients with active psoriatic arthritis.

Related Journal Club Videos Module

journalimg

Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23

IL-23
journalimg

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

IL-23
sectionimg
dotsimg

Download the app and start using it now.

appstore Download on the App Store playstore GET IT ON Google Play